Mizuho Raises Nurix Price Target to $34 After Roche Deal

Mizuho analysts raised the price target for Nurix Therapeutics to $34 following the company's strategic collaboration with Roche. The revision is based on expectations that the deal will positively contribute to Nurix's drug development portfolio and financial outlook. Analysts noted that the agreement with Roche validates the value of Nurix's targeted protein degradation (TPD) platform and provides the company with a significant upfront payment and potential milestone payments. This strengthens Nurix's near-term cash flow while enhancing its long-term growth potential. Mizuho emphasized that the new price target represents a substantial premium over the company's current market value, driven by the synergies created by the Roche deal. Analysts expect Nurix's leading position in TPD and the support of a partner like Roche to positively impact the company's future revenue streams. Nurix shares rose following the announcement of the deal, and Mizuho's price target revision was well received by investors. The company's stock continues to trade below the target price in recent transactions. This is not an investment recommendation.